Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.

Whitworth, Pat

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping. [electronic resource] - Annals of surgical oncology Mar 2017 - 669-675 p. digital

Publication Type: Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study

1534-4681

10.1245/s10434-016-5600-x doi


Adult
Aged
Aged, 80 and over
Anastrozole
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Aromatase Inhibitors--therapeutic use
Breast Neoplasms--classification
Bridged-Ring Compounds--administration & dosage
Chemotherapy, Adjuvant
Clinical Decision-Making
Cyclophosphamide--administration & dosage
Docetaxel
Doxorubicin--administration & dosage
Female
Gene Expression Profiling
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Letrozole
Mastectomy, Segmental
Middle Aged
Molecular Typing--methods
Neoadjuvant Therapy
Nitriles--administration & dosage
Prospective Studies
Receptor, ErbB-2--metabolism
Receptors, Estrogen--metabolism
Receptors, Progesterone--metabolism
Registries
Tamoxifen--administration & dosage
Taxoids--administration & dosage
Treatment Outcome
Triazoles--administration & dosage
Young Adult